⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
Form 8-K
sec.gov
URGN
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
globenewswire.com
URGN
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
globenewswire.com
URGN
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
globenewswire.com
URGN
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
globenewswire.com
URGN
Form 8-K
sec.gov
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
URGN
Form 8-K
sec.gov
URGN
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
globenewswire.com
URGN
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
URGN